

Capstone Therapeutics Corp.  
Form SC 13G  
February 11, 2019

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**SCHEDULE 13G**

(Rule 13d-102)

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(b)**

(Amendment No. \_\_)\*

Capstone Therapeutics Corp.  
(Name of Issuer)

Common Stock  
(Title of Class of Securities)

14068E109  
(CUSIP Number)

February 11, 2019  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

þ Rule 13d-1(c)

¨ Rule 13d-1(d)

Page 1 of 5

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**SCHEDULE 13G**

**CUSIP No. 14068E109 Page 2 of 5 Pages**

**NAME OF REPORTING PERSON**

**1**

Alimco Financial Corporation

**2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*** (a)   
(b)

**3 SEC USE ONLY**

**4 CITIZENSHIP OR PLACE OF ORGANIZATION**

Delaware

**NUMBER OF SHARES** **5 SOLE VOTING POWER**  
103,000

**BENEFICIALLY OWNED BY EACH** **6 SHARED VOTING POWER**  
0

**REPORTING PERSON** **7 SOLE DISPOSITIVE POWER**  
103,000

**WITH** **8 SHARED DISPOSITIVE POWER**  
0

**9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON**  
103,000

**10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES** ..  
**11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)**

0.2%<sup>1</sup>

**12 TYPE OF REPORTING PERSON**

CO\*\*

\*\* See Item 4.

<sup>1</sup> The percentage reported in this Schedule 13G is based upon 54,385,411 shares of Common Stock outstanding according to the Form 10-Q filed by the Issuer on November 6, 2018.



Explanatory Note:

This Schedule 13G is filed by Alimco Financial Corporation ("Alimco") and does not include certain shares of common stock of the Issuer ("Shares") reported separately by Mr. Neil S. Subin ("Mr. Subin"). Mr. Subin has filed a Schedule 13G with respect to Shares held by certain entities owned by or for the benefit of the family of the late Mr. Lloyd I. Miller, III (the "Miller Entities"). Certain of the Miller Entities hold approximately 85% of the outstanding shares of common stock of Alimco. Alimco and Mr. Subin respectively disclaim (i) the existence of, and membership in, a "group" under Section 13(d)(3) of the Securities Exchange Act of 1934, and (ii) beneficial ownership of the securities reported by the other reporting person.

Item 1(a). Name of Issuer:	Capstone Therapeutics Corp.
Item 1(b). Address of Issuers' Principal Executive Offices:	1275 W. Washington Street Suite 104 Tempe, AZ 85281
Item 2(a). Name of Person Filing:	Alimco Financial Corporation
Item 2(b). Address of Principal Business Office or, if None, Residence:	3300 South Dixie Highway Suite 1-365 West Palm Beach, Florida 33405
Item 2(c). Citizenship:	U.S.A.
Item 2(d). Title of Class of Securities:	Common Stock
Item 2(e). CUSIP Number:	14068E109

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b) OR 13d-2(b) or (c), CHECK WHETHER THE PERSON FILING IS A:

Not Applicable, this statement is filed pursuant to 13d-1(c)

Item 4. OWNERSHIP:

(a) As of the date hereof Alimco beneficially owns 103,000 Shares.

(b)0.2%

(c)(i)sole voting power: 103,000

(ii)shared voting power: 0

(iii)sole dispositive power: 103,000

(iv)shared dispositive power: 0

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

Not Applicable

Page 4 of 5

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

No person other than Alimco has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the reported securities.

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

Not Applicable

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

See Explanatory Note

Item 9. NOTICE OF DISSOLUTION OF GROUP:

Not Applicable

Item 10. CERTIFICATION:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 5 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2019 ALIMCO FINANCIAL  
CORPORATION

By: /s/ Alan B. Howe  
Name: Alan B. Howe  
Title: Chief Executive Officer